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Previously, we deﬁned SCY1-like 1 binding protein 1 (SCYL1-BP1) to be a substrate of Pirh2 that
binds to mouse double minute gene number 2 (MDM2). In the current study, we found that an
increase in SCYL1-BP1 protein levels caused a parallel change in the amount of p53 protein due to
the inhibition by SCYL-BP1 of MDM2-mediated p53 ubiquitination. SCYL1-BP1 was not able to alter
the ubiquitination of p53 by human papillomavirus protein E6, indicating that the effect was spe-
ciﬁc for MDM2. Increases in the level of SCYL1-BP1 protein in cells led to the greater transcriptional
activation of p21 and gadd45, reduced rate of cellular proliferation, increased levels of apoptosis and
inhibition of tumorigenicity. Thus, we propose that SCYL1-BP1 is a novel regulator of the MDM2-p53
feedback loop and that it may be a potential tumor suppressor.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The tumor suppressor protein p53 is a transcription factor that
acts through a number of pathways to protect cells from malignant
transformation [11]. As a sequence-speciﬁc DNA-binding protein,
upon activation, p53 triggers the transcription of its target genes
through binding to speciﬁc DNA consensus sequences, such as
those found in the genes p21, gadd45, and PUMA [20]. These p53
target genes subsequently regulate cell cycle progression, cell
death, DNA repair and DNA replication to maintain genomic stabil-
ity and prevent tumorigenesis. However, under normal conditions,
the p53 protein is short-lived, primarily due to mouse double min-
ute gene number 2 (MDM2)-mediated ubiquitination and degrada-
tion. MDM2, an E3 ubiquitin ligase, is also a transcriptional target
of p53. MDM2 binds to the transactivation domain of p53 and
inhibits p53-mediated transcription, shuttles p53 out of the nu-
cleus and targets p53 for ubiquitin-mediated proteolysis [14]. Be-
sides MDM2, p53 is also targeted by other ubiquitin ligases,chemical Societies. Published by E
number 2; SCYL1-BP1, SCY1-
, San Antonio, TX 78245, USA.
hanghai 200433, China. Fax:
o@fudan.edu.cn (K. Huo).including COP1 [7] Pirh2 [10] and E6AP [17], among others,
although the regulation of these enzymes is less clear.
SCY1-like 1 binding protein 1 (SCYL1-BP1), which was originally
cloned in our lab, was found to interact with both Pirh2 [21] and
MDM2 [19]. Additionally, we found that SCYL1-BP1 was a sub-
strate of Pirh2, but not MDM2. However, by binding to MDM2,
SCYL1-BP1 induced MDM2 self-ubiquitination and thus a reduc-
tion in MDM2 protein levels. Because p53 is a common substrate
of both Pirh2 and MDM2, we hypothesized that SCYL1-BP1 expres-
sion may affect p53 protein levels. In this paper, we demonstrate
that SCYL1-BP1 stabilized the protein level of p53 in vivo and
inhibited MDM2-dependent p53 ubiquitination. Moreover, we also
identiﬁed a potential tumor-suppressive property of SCYL1-BP1.
2. Results
2.1. SCYL1-BP1 promoted p53 protein stabilization
Previously, we found that SCYL1-BP1 induced MDM2 self-ubiq-
uitination and protein reduction [19]. Because MDM2 is a key E3
ubiquitin ligase of p53, we wanted to know whether or not
SCYL1-BP1 was able to affect p53 protein level and/or cellular func-
tion. We ﬁrst investigated the effect of SCYL1-BP1 on the steady-
state levels of p53 in the cell line sk-hep1, which has endogenous
wild-type p53 expression intact. The endogenous p53 protein level
increased concomitantly with the increase in the protein level of
SCYL1-BP1 (Fig. 1A). We also tested the endogenous p53 proteinlsevier B.V. All rights reserved.
Fig. 1. SCYL1-BP1 stabilized p53 protein expression. (A) The overexpression of SCYL1-BP1 induced an increase in the p53 protein level in vivo. sk-hep1 cells were transiently
transfected with increasing levels of a SCYL1-BP1-expressing plasmid. When necessary, the cells were treated with 30-lM MG132 for 6 h before harvest. The expression of
p53, GAPDH and Myc-SCYL1-BP1 were assayed by western blot. (B) sk-hep1 cells were stably transfected with GFP-SCYL1-BP1 or GFPc (empty vector) plasmids, as indicated.
Protein lysates were analyzed by western blotting for p53, endogenous SCYL1-BP1, GFP tagged SCYL1-BP1 and GAPDH. (C) SCYL1-BP1 increased the half-life of p53. sk-hep1
cells were transfected with or without Myc-SCYL1-BP1. At 48 h post-transfection, the cells were treated with 50-lg/ml cycloheximide (CHX) for the indicated times. Lysates
were prepared and analyzed by western blotting for p53 and the GAPDH loading control. (D) The p53 expression levels following cycloheximide treatment in cells expressing
either Myc-SCYL1-BP1 (solid squares) or Myc-GFP alone (triangles), adjusted for the levels of loading control GAPDH, were plotted. (E) sk-hep1 cells were transfected with or
without Myc-SCYL1-BP1 expression vector. As indicated, cells were treated with 2-mM CPT for 2 h to induce DNA damage. The lysates were analyzed for the phosphorylation
status of Ser15 in p53 (pS15-p53), total p53 (p53), Myc-SCYL1-BP1 and GAPDH. (F) SCYL1-BP1 did not affect the p53 mRNA level. The sk-hep1 cells were transfected with
SCYL1-BP1-expression plasmids as indicated. The relative expression of p53 was measured by quantitative real-time PCR, and then normalized to expression of gapdh. The
values represented fold increase or decrease relative to untreated sk-hep1 cells.
4320 J. Yan et al. / FEBS Letters 584 (2010) 4319–4324levels in both sk-hep1-pEGFPc and sk-hep1-pEGFP-SCYL1-BP1 sta-
bly transfected cells. The overexpression of SCYL1-BP1 resulted in a
similar increase in the amount of p53 (Fig. 1B). Moreover, the
upregulation of p53 by SCYL1-BP1 was attenuated when the cells
were treated with the proteasome inhibitor MG132 (Fig. 1A, lanes
1 and 6), suggesting that the regulation of p53 by SCYL1-BP1 was
probably accomplished through an effect on protein turnover. To
further examine this possibility, the half-life of p53 with or with-
out SCYL1-BP1 overexpression was analyzed. The half-life of p53
was found to be extended by ectopically expressing SCYL1-BP1
(Fig. 1C and D). The data in Fig. 1F conﬁrmed that upregulation
of the p53 response was not correlated with an increased p53
mRNA level.
It is also possible that even a slight increase in SCYL1-BP1
expression could result in genotoxic stress, leading to p53 activa-
tion and stabilization. A hallmark of DNA damage is phosphoryla-
tion at the Ser15 residue of p53 [8]. To address this possibility, we
assessed the Ser15 phosphorylation status of p53 as well as the to-
tal p53 levels. As shown in Fig. 1E, SCYL1-BP1 increased the level of
total p53 signiﬁcantly, but the level of p53 that was phosphory-
lated at Ser15 remained unaltered (Fig. 1E, lanes 1 and 2). In con-
trast, after treatment with the DNA-damaging agent cisplatin,
similar increases in the total and Ser15-speciﬁc phosphorylation
of p53 were noted in cells that were transfected with or without
Myc-SCYL1-BP1 (Fig. 1E, lanes 3 and 4). These data indicate that
SCYL1-BP1 increased p53 levels via a pathway that was most likelydistinct from pathways that are utilized by cells undergoing geno-
toxic stress.
2.2. SCYL1-BP1 stabilized the protein level of p53 by inhibiting MDM2-
mediated ubiquitination
The primary pathway of p53 turnover is through ubiquitination
by MDM2 and subsequent proteasomal degradation. Because our
previous data suggested that SCYL1-BP1 might interfere with this
pathway, we examined the effect of MDM2 on the ability of
SCYL1-BP1 to modulate p53 levels. We expressed constant levels
of exotic p53 in embryonic ﬁbroblasts from p53/MDM2 double
knockout mice (2KO-MEFs) for this investigation. The results
showed that SCYL1-BP1 had a much more pronounced effect on
p53 levels in the 2KO-MEFs cells expressing MDM2 (Fig. 2A). Sim-
ilarly, the obviously diminished ubiquitination of p53 caused by
SCYL1-BP1 was detected only in the presence of MDM2 (Fig. 2B,
lane 3 and 4). To expand on this data, we assessed the effect of
SCYL1-BP1 on p53 ubiquitination in sk-hep1 cells (p53 wild-type)
that were treated with MG132. The data show that the ubiquitinat-
ed forms of p53 were impaired in SCYL1-BP1-expressing cells com-
pared with control cells, although the total levels of endogenous
p53 were comparable (Fig. 2C).
It was also possible that the expression of SCYL1-BP1 could
have altered the entire ubiquitination pathway in the cells. To ex-
clude this possibility, we employed HeLa cells, in which p53 is
Fig. 2. SCYL1-BP1 inhibited MDM2-dependent degradation of p53. (A) The stabilization of p53 by SCYL1-BP1 was dependant on MDM2. 2KO-MEFs cells were transfected
with plasmids expressing p53, Myc-MDM2 or GFP-SCYL1-BP1, as indicated. The protein level of p53 was analyzed by western blotting. (B) SCYL1-BP1 impaired MDM2-
mediated p53 ubiquitination in vivo. 2KO-MEFs cells were co-transfected with the plasmids indicated and then were cultured in the presence of MG132. The ubiquitinated
conjugates puriﬁed by Ni-NTA-agarose beads were analyzed using anti-p53 antibodies. The cell lysates (10% input) were analyzed by western blotting using the indicated
antibodies. (C) SCYL1-BP1 suppresses p53 ubiquitination in sk-hep1 cells. The sk-hep1 cells were transfected with His-Ub and Myc-SCYL1-BP1 plasmids. The His-tagged
(ubiquitinated) species were then immunoprobed for the presence of p53. Total lysates were probed for p53 (total), Myc-SCYL1-BP1 and GAPDH. (D) SCYL1-BP1 had no effect
on p53 protein level in HeLa cells. HeLa cells were transfected with p53 (lane 3 and 4) and Myc-SCYL1-BP1 plasmids as indicated. Total lysates were probed for SCYL1-BP1,
p53 and GAPDH. (E) SCYL1-BP1 overexpression did not inhibit p53 ubiquitination in HeLa cells. HeLa cells were transfected with p53, His-Ub and Myc-SCYL1-BP1 plasmids.
The His-tagged (ubiquitinated) species were isolated and then immunoprobed for p53. Total lysates were analyzed for SCYL1-BP1, total p53 and GAPDH. The same total DNA
amount was kept constant by transfection of empty vector in every individual experiment.
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[17]. As shown in Fig. 2D, SCYL1-BP1 overexpression failed to sta-
bilize p53 in HeLa cells, indicating that the activation of p53 by
SCYL1-BP1 was speciﬁcally occurring through the MDM2 pathway,
rather than by affecting the whole ubiquitination process. The
same ubiquitination pattern of p53 in HeLa cells occurred irrespec-
tive of the expression of SCYL1-BP1 (Fig. 2E), which was in agree-
ment with our previous data.
2.3. SCYL1-BP1 affected the transcriptional activity of p53
As is well known, p53 is an important transcription factor that
is present in very low amounts in normal cells. The activation of
p53 results in the transactivation of many target genes that regu-
late corresponding biological processes. Thus, we also assessed
the transcriptional activation ability of p53 under conditions of
SCYL1-BP1 overexpression using p21 and gadd45 luciferase report-
ers that contain p53-responsive elements.
By transfecting 2KO-MEF cells with the plasmids cocktails that
are illustrated in Fig. 3A and B, we found that SCYL1-BP1 had no
signiﬁcant effect on reporter activity without MDM2. However,
in the presence of MDM2, although the reporter activity was de-
creased signiﬁcantly by MDM2, SCYL1-BP1 was able to rescue
the reduction in p21 and gadd45 transcription. The results show
that SCYL1-BP1 stabilized functional p53 and promoted its tran-
scriptional activity in an MDM2-dependent manner.2.4. SCYL1-BP1 promoted apoptosis, inhibited cell growth
and prevented tumorigenicity
Given its potential connection to p53, we tested whether
SCYL1-BP1 may be a tumor suppressor in cell lines having wild-
type p53. First, we established sk-hep1 cell lines stably expressing
either GFP or GFP-SCYL1-BP1. We then measured the cellular pro-
liferation rate and found that exogenous SCYL1-BP1 dramatically
inhibited the proliferation of the sk-hep1 cells (Fig. 4A). Next, we
examined whether SCYL1-BP1 induced apoptosis in the sk-hep1
cells. Flow cytometry was used to compare cells with different
genotypes under normal conditions or the following types of geno-
toxic stress: Act. D or 5-FU treatment. Under these conditions, cells
expressing GFPc-SCYL1-BP1 were more apoptotic than those
expressing GFP (Fig. 4B). Furthermore, we tested the tumor-sup-
pressive ability of SCYL1-BP1 in nude mice. We used another p53
wild-type cell line, BEL7402, to generate BEL7402-pEGFPc,
BEL7402-pEGFP-mSCYL1-BP1 and BEL7402-pEGFP-hSCYL1-BP1
stable transfectants, and injected each of BEL7402 transfectants
into six male BALB/c nude mice. Tumor growth was monitored
for 21 days, at which time the mice were sacriﬁced and explants
were established from the harvested tumors. As shown in Fig. 4C,
all of SCYL1-BP1-expressing clones showed a drastic reduction in
tumorigenicity. These results emphasize the important role of
SCYL1-BP1 in the p53 pathway and suggest that SCYL1-BP1 may
be a novel target for future tumor therapies.
Fig. 3. The effect of SCYL1-BP1 on the transcriptional activity of p53 was dependent on MDM2. 2KO-MEFs cells were transfected with a p53 responsive luciferase reporter
derived from (A) p21 or (B) gadd45, and plasmids expressing human p53, MDM2 and Myc-BP1 (+ or ++ indicates that a low or high dose was given, respectively), as indicated,
and luciferase activity was assayed. The results were normalized to Renilla luciferase activity, and represent the mean ± S.D. of three independent experiments.
Fig. 4. SCYL1-BP1 inhibited cell growth, promoted apoptosis and prevented tumorigenicity. (A) SCYL1-BP1 inhibited cellular proliferation as determined by the CCK-8 kit. The
sk-hep1 cells that were stably transfected with pEGFPc or pEGFPc-SCYL1-BP1 were plated in 96-wells. The average values of the absorbance at 450 nm derived from four
independent experiments for each sample were shown in panel A. (B) SCYL1-BP1 promoted apoptosis in sk-hep1 cells. sk-hep1 cells were transfected with pEGFPc or pEGFPc-
SCYL1-BP1 plasmids as indicated. Then, cells were treated with 10-nM Actinomycin D (Act. D) or 20-lg/ml 5-FU for 12 h to induce the genotoxic stress. Apoptosis was
measured by ﬂow cytometric analysis of propidium iodide staining. (C) SCYL1-BP1 suppressed tumor growth after transplantation into nude mice. BEL7402 cells were stably
transfected pEGFPc, pEGFPc-mSCYL1-BP1 or pEGFPc-hSCYL1-BP1 plasmids. Stably transfected cells were then injected into nude mice. Three weeks later, photographs were
taken (left panel). Tumors were removed and weighed. Results are shown as the mean ± S.D. of tumor weight (right panel).
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We previously used SCYL1 (also known as NTKL) as bait in a
yeast two-hybrid assay to discover binding partners. We identiﬁed
a protein named SCYL1-BP1, which is soluble, highly conserved
and widely expressed in many tissues [6]. However, the speciﬁc
function of SCYL1-BP1 remained unknown. In this study, we dem-
onstrated that SCYL1-BP1 slowed down the cellular proliferation
rate, induced apoptosis, and inhibited tumorigenicity. As for how
exactly SCYL1-BP1 exercises these functions, we have shown that
SCYL1-BP1 elevated the level of p53 protein by impairing p53 ubiq-
uitination and degradation. Several E3 ubiquitin ligases for p53
regulation have been reported, including MDM2 [9], COP1 [7],
E6AP [16] and Pirh2 [10]. Our experiments demonstrated that
the ability of SCYL1-BP1 to activate p53 is MDM2-dependent. Par-
allel tests, including E6AP in HeLa cells, effectively exclude the pos-
sibility of a general inhibition by SCYL1-BP1 of p53 ubiquitination
and degradation, and established a speciﬁc role for SCYL1-BP1 in
the MDM2-p53 pathway.
We previously found that SCYL1-BP1 binds to MDM2 and pro-
motes the self-ubiquitination of MDM2 [19]. The ability of
SCYL1-BP1 to suppress MDM2 ubiquitination of p53, but promote
ubiquitination of MDM2 itself, is interesting. In contrast to C23
[15] and other ribosomal proteins [3,18], it seems that SCYL1-
BP1 selectively affects the ubiquitination of MDM2 target proteins.
A similar phenomenon was also observed with regard to the effect
of MTBP on p53-MDM2 loop [2]. MTBP promotes the ubiquitina-
tion of p53 but inhibits the ubiquitination of MDM2. However,
MTBP binds to the region between amino acids 167 and 304,
encompassing the central acidic region of MDM2 [1]. Moreover,
NS [5] and C23 [15] also associate with this region of MDM2 and
inhibit MDM2 E3 ligase activity on both itself and p53. All of these
data suggests that the central acidic region of MDM2 plays an
important, yet diverse, regulatory function on the ubiquitination
activity of MDM2. A second p53 binding site has been identiﬁed
in MDM2 (amino acid 211–361), including the acidic domain and
the zinc ﬁnger domain [12]. The interaction between the central
domain of MDM2 and the core domain of p53 is critical for the
ubiquitination and degradation of p53 [12]. We propose that the
exogenously overexpressed SCYL1-BP1 may have bound to the
central acidic domain of MDM2 and occupied the second p53 bind-
ing site on MDM2, although p53 can also loosely bind to the N-ter-
minus of MDM2 with its own N-terminus. Then, it would be moreFig. 5. A schematic model illustrates the potential mechanism underlying the distin
ubiquitination of p53.difﬁcult for MDM2 to deliver the ubiquitin chains onto p53. In con-
trast, binding to SCYL1-BP1 may alter the conformation of MDM2,
which in turn would facilitate the attachment of ubiquitin chains
to its own lysines. As shown in Fig. 5, SCYL1-BP1, MDM2, p53
and the poly-ubiquitin chain may form a transient complex in
the cells. We conﬁrmed the binding in vitro (data not shown),
but whether it is possible to form such a complex under natural
physiological conditions is still a topic of research in our lab.
In conclusion, we found that SCYL1-BP1 stabilized p53 by inhib-
iting MDM2-mediated p53 ubiquitination and degradation and
that this resulted in apoptosis, cell growth inhibition and tumor
prevention.
4. Materials and methods
4.1. Expression plasmids
Human SCYL1-BP1 cDNA [6] was derived from a human fetal li-
ver cDNA library (Clontech) and cloned into the pCMV-Myc (Strat-
agene) and pEGFPc-1 (Clontech) vectors. The p53 expression
plasmid was constructed by cloning the full-length human p53 se-
quence into the pcDNA3.0 vector (Invitrogen). His-Ub was gener-
ously provided by Dr. H. Lu [4].
4.2. Cell lines
Human sk-hep1, HepG2, H1299, HEK293 and BEL7402 cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 50-U/ml penicil-
lin, and 0.1 mg/ml streptomycin at 37 C in a 5% CO2 humidiﬁed
atmosphere. The p53 and MDM2 double knockout MEFs (2KO-
MEFs) were a gift from Dr. G. Lozano [13].
For the transient transfections, cells were transfected with plas-
mids using Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer’s protocols. To generate stable cell lines, sk-hep1 cells
were seeded at 5  105 cells per 60-mm plate and transfected with
2 lg of GFP-SCYL1-BP1 or 1 lg of GFPc vectors. Post-transfection
(18 h), the cells were replated at a density of 104 cells per 10-cm
dish, in duplicates. GFP-expressing cells were selected in DMEM
media containing 1200-lg/ml G418 (MERCK) for 21 days, with
the drug-containing media replaced every week. Individual clones
were subsequently isolated and expanded over a two to four week-
long period.ct roles of SCYL1-BP1 on MDM2 auto-ubiquitination and the MDM2-mediated
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The primary antibodies used for immunoprecipitation or wes-
tern blotting were as follows: rabbit polyclonal anti-Myc antibody
(Santa Cruz), mouse monoclonal anti-GFP (Santa Cruz), mouse
monoclonal anti-p53 (DO-7, Abcam) and rabbit polyclonal
anti-p53, phosphorylated on Ser15 (pS15p53, Cell Signaling
Technology).
4.4. Luciferase assays
Luciferase reporter constructs containing the p53 responsive se-
quence p21-Luc was a gift from Dr. Moshe Oren [9], while gadd45-
Luc was from Dr. John A. Di Battista [8].
For luciferase assays, 2KO cells were seeded in 24-well plates
24 h before transfection. The cells were transfected with the plas-
mids using Lipofectamine 2000 (Invitrogen) according to manufac-
turer’s instructions at 60% conﬂuence (with 200 ng of reporter
constructs). When the cells were ready, 50 ng of the p53 and
100 ng of the MDM2 plasmids were co-transfected. Total plasmid
DNA per well was adjusted to an equal level by adding empty vec-
tor. The cells were harvested at 48 h post-transfection and pre-
pared using the Dual Luciferase Assay System (Promega)
following the manufacturer’s protocol. The luciferase activity was
measured in a Laser Capture Microdissection (LCM) System Veri-
tas™ (Turner Biosystems). For each construct, the relative lucifer-
ase activity was deﬁned as the mean value of the ﬁreﬂy
luciferase/Renilla luciferase ratios that were obtained from at least
four independent experiments.
4.5. Apoptosis
For apoptosis analysis, cells under normal conditions or treated
with either 10-nM Actinomycin D (Act. D) or 20-lg/ml ﬂuorouracil
(5-FU) for 12 h prior to harvest were washed twice in phosphate-
buffered saline (PBS), ﬁxed with 4% PFA and permeabilized in
0.1% Triton X-100/PBS on ice for 10 min. The ﬁxed cells were then
washed and stained with a propidium iodide solution containing
50-lg/ml propidium iodide, 0.05% Triton X-100, 37-lg/ml EDTA,
and 100-U/ml ribonuclease in PBS. After incubation for 45 min at
37 C, the DNA content was determined by quantitative ﬂow
cytometry using the standard optics of the FACScan ﬂow cytometer
(Becton-Dickinson FACStar). GFP-positive cells were gated and the
percentage of apoptotic cells were quantitated from the sub-G1
events.
4.6. Cell growth rate analysis
Cell growth rate was determined by using the Cell Counting Kit-
8 (CCK-8, Dojindo Laboratories) according to the manufacturer’s
instructions. Cells were cultured in a 96-well plate and every
24 h, four of the wells were treated with 10 ll of CCK-8 solution
per well and incubated for 2 h at 37 C over 6 days. The amount
of formazan dye generated by cellular dehydrogenase activity
was then measured by absorbance at 450 nm with a microplate
ﬂuorometer.
4.7. Tumorigenicity assay
The tumorigenicity assays were performed using BALB/c nude
mice that were purchased from the Shanghai Laboratory AnimalCenter of China. The control (BEL7402-pEGFPc), BEL7402-pEGFPc-
mSCYL1-BP1 and BEL7402-pEGFPc-hSCYL1-BP1 cells were injected
subcutaneously into the ﬂanks of the mice (106 cells/injection site,
six mice/cell line). After 3 weeks, photographs were taken and tu-
mors were harvested and individually weighed after the mice were
anesthetized. Data are presented as tumor weight (mean ± S.D.).
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